Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies
ConclusionsSerum peak concentrations of bevacizumab in children under the age of 3 years with CNS malignancies are in a similar magnitude to that found in older children and adults. Thus, a dosing schedule of bevacizumab 10 mg/kg every 2 weeks can be considered sufficient and safe, even in very young children. We further show that very young children with CNS malignancies show a markedly reduced plasma clearance, possibly related to lower body weight or differences in clearance mechanisms of antibodies. (Source: Drugs in R&D)
Source: Drugs in R&D - June 2, 2017 Category: Drugs & Pharmacology Source Type: research
Comparison of Generic Drug Reviews for Marketing Authorization between Japan and Canada
ConclusionsThe results clarified the future challenges of generic drug reviews, and the differences highlighted by this survey will be important considerations for the future. This is the first article to present and discuss the details of generic drug reviews between Japan and Canada. (Source: Drugs in R&D)
Source: Drugs in R&D - June 2, 2017 Category: Drugs & Pharmacology Source Type: research
A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis
ConclusionTeneligliptin treatment significantly reduced plasma levels of RLP-C, FPG, and HbA1c in patients with diabetes with CKD who are undergoing hemodialysis. (Source: Drugs in R&D)
Source: Drugs in R&D - June 2, 2017 Category: Drugs & Pharmacology Source Type: research
A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma
ConclusionsCombination therapy with sorafenib and 5-FU appears to be well tolerated and may have the potential to be an option for advanced HCC. (Source: Drugs in R&D)
Source: Drugs in R&D - June 1, 2017 Category: Drugs & Pharmacology Source Type: research
A Comparative Study of the Hemoglobin-Maintaining Effects Between Epoetin- β Pegol and Darbepoetin-α in Patients with Chronic Kidney Disease During 3 Months Before Dialysis Initiation
ConclusionsOur results suggest that CERA may be more effective than DA in maintaining hemoglobin levels in patients with CKD during 3 months before dialysis initiation. (Source: Drugs in R&D)
Source: Drugs in R&D - May 25, 2017 Category: Drugs & Pharmacology Source Type: research
